Biodistribution and dosimetry studies form the cornerstone of radiopharmaceutical development, bridging the gap between tracer design and safe clinical application by quantifying where a radiolabeled compound travels in the body and how much radiation it deposits in each organ. Protheragen delivers end-to-end biodistribution and dosimetry solutions that empower developers to characterize radiotracer pharmacokinetics, estimate human radiation doses, and make informed go/no-go decisions before first-in-human trials.
Biodistribution refers to the spatial and temporal distribution of a radiopharmaceutical throughout the body following administration. In nuclear medicine, this parameter is fundamental because the diagnostic utility of an imaging agent and the therapeutic efficacy of a radioligand depend entirely on how selectively and persistently the compound accumulates in target tissues versus healthy organs. Biodistribution is influenced by multiple factors including the physicochemical properties of the radiopharmaceutical, the route of administration, pathophysiological conditions, and potential drug interactions. Preclinical biodistribution studies typically employ rodent models and combine in vivo molecular imaging—such as micro-PET and micro-SPECT—with ex vivo techniques including gamma counting of dissected tissues, autoradiography, and radiometabolite analysis to build a comprehensive pharmacokinetic profile.
Fig 1. Dosimetry workflow summary. (Carter, Lukas M., et al., 2024)
| Topic Area | Current Status | Implication for Development |
|---|---|---|
| Personalized Dosimetry in RPT | Shift from fixed activity to patient-specific dosing based on quantitative imaging and absorbed dose calculations. | Enables optimization of therapeutic efficacy while minimizing toxicity; supported by EC Directive 2013/59/Euratom. |
| Alpha-Emitter Dosimetry | Sub-organ and cellular-level dosimetry is required for TAT agents (e.g., 225Ac, 212Pb) due to short alpha-particle range. | Standard MIRD organ-level estimates may underestimate toxicity; microdosimetry and autoradiography are increasingly necessary. |
| Theranostics Paradigm | Diagnostic/therapeutic pairs (e.g., 68Ga/177Lu-PSMA) allow imaging-based prediction of therapeutic biodistribution and dose. | Reduces uncertainty in dose estimation and supports companion diagnostic development alongside therapeutics. |
| Preclinical Imaging Integration | Micro-PET/SPECT/CT enables longitudinal, non-invasive biodistribution quantification in rodent models. | Reduces animal usage (3Rs principle), provides time-resolved data, and improves translational confidence. |
| AI in Dosimetry | Machine learning approaches are being developed for automated segmentation, kinetic modeling, and dose prediction. | May streamline clinical adoption by reducing manual processing time and inter-operator variability. |
| Standardization Challenges | Heterogeneity in imaging protocols, software platforms, and phantom models persists across institutions. | Highlights the need for harmonized guidelines to ensure reproducible and comparable dosimetry data for regulatory review. |
| Pediatric Considerations | Children exhibit greater physiological variability and heightened radiosensitivity; adult-derived dose cards often apply poorly. | Pediatric-specific dosimetry models and dose scaling methods remain an unmet need in clinical translation. |
| Ex Vivo vs. In Vivo Methods | Ex Vivo gamma counting remains the gold standard for preclinical quantification; in vivo imaging complements with temporal resolution. | Hybrid approaches combining both methods yield the most robust preclinical dosimetry estimates. |
At Protheragen, we recognize that robust biodistribution and dosimetry data are not merely regulatory checkboxes—they are the scientific foundation upon which safe and effective radiopharmaceuticals are built. Our integrated preclinical service platform combines advanced molecular imaging capabilities, quantitative ex vivo analytics, and dosimetry modeling expertise to deliver comprehensive pharmacokinetic and radiation dose profiles for your radiolabeled compounds. Whether you are developing a novel diagnostic tracer or a next-generation therapeutic radioligand, Protheragen provides the precise, reproducible data you need to advance confidently from bench to bedside.
We conduct comprehensive biodistribution evaluations in rodent models using both in vivo and ex vivo methodologies. Our in vivo imaging suite includes micro-PET, micro-SPECT, and micro-CT for longitudinal, non-invasive quantification of radiotracer uptake across all major organs and tumor lesions. Complementary ex vivo studies involve tissue harvesting, gamma counting, and whole-body autoradiography to provide high-fidelity activity concentration data. We support a wide range of radionuclides including 18F, 68Ga, 89Zr, 99mTc, 111In, 177Lu, 131I, 225Ac, and 212Pb.
Using biodistribution data as input, we perform organ-level absorbed dose calculations following the MIRD schema and ICRP guidelines. Our team utilizes established software platforms such as OLINDA/EXM and MIRDcalc, alongside custom pharmacokinetic modeling, to extrapolate preclinical animal data to human dose estimates. These calculations identify dose-limiting organs, estimate effective whole-body dose, and support first-in-human activity selection and regulatory dossier preparation.
Our small-animal imaging services provide time-resolved, quantitative data on radiopharmaceutical pharmacokinetics. We perform dynamic and static imaging protocols with calibrated scanners, apply partial volume and attenuation corrections, and generate time-activity curves for all source organs. This approach is particularly valuable for theranostic pairs, where diagnostic imaging data directly inform therapeutic dose planning.
For applications requiring higher spatial resolution or absolute activity quantification, we offer ex vivo gamma counting of dissected tissues, blood, and excreta. Digital autoradiography services provide sub-millimeter resolution maps of radiotracer distribution within tissue sections—critical for evaluating tumor heterogeneity, sub-organ dose distribution, and off-target accumulation in complex tissues such as bone marrow and lymph nodes.
Understanding the metabolic fate of a radiopharmaceutical is essential for accurate dosimetry and safety assessment. We perform in vitro and in vivo radiometabolite analysis using HPLC-radio-detection to characterize the chemical stability of your compound in plasma and tissues, identify radioactive metabolites, and evaluate their potential contribution to overall radiation dose.
Targeted alpha therapy presents unique dosimetry challenges due to the short range and high linear energy transfer of alpha particles. Protheragen offers specialized microdosimetry services including digital autoradiography with near-cellular resolution, sub-organ dose mapping, and integration with histological staining to correlate dose distribution with tissue morphology. These data are essential for interpreting therapeutic efficacy and predicting normal-tissue toxicity for alpha-emitting radiopharmaceuticals.
Our biodistribution and dosimetry service follows a structured, milestone-driven workflow that ensures scientific rigor, regulatory compliance, and seamless integration with your broader radiopharmaceutical development program. Each project begins with a detailed consultation to align study objectives with your clinical translation strategy, followed by execution through imaging, analytics, modeling, and reporting.
Ready to advance your radiopharmaceutical program with rigorous biodistribution and dosimetry data? Contact us today to discuss your project requirements and learn how Protheragen can support your journey from preclinical characterization to clinical translation. Our team is prepared to design a customized study plan that aligns with your development timeline and regulatory strategy. Reach out to us now and take the next step toward bringing your radiopharmaceutical innovation to patients.
Reference